NUVL Nuvalent, Inc.

Nuvalent Inc is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets.

$20.07  -0.83 (-3.97%)
As of 12/03/2021 15:59:56 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/09/2017
Outstanding shares:  42,848,715
Average volume:  53,079
Market cap:   $895,538,143
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    670703107
ISIN:        US6707031075
Sedol:      BMVBZD3
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.20
PS ratio:   0.00
Return on equity:   -11.83%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy